Tuesday, 14 August 2012

Cardene SR


Generic Name: nicardipine (nye KAR di peen)

Brand Names: Cardene, Cardene SR


What is Cardene SR (nicardipine)?

Nicardipine is in a class of drugs called calcium channel blockers. Nicardipine relaxes (widens) your blood vessels, which makes it easier for the heart to pump and reduces its workload.


Nicardipine is used to treat hypertension (high blood pressure) and angina (chest pain).


Nicardipine may also be used for purposes other than those listed in this medication guide.


What is the most important information I should know about Cardene SR (nicardipine)?


Do not stop taking nicardipine without first talking to your doctor, even if you begin to feel better. If you stop taking the medication, your condition could become worse. Do not crush, chew, or break the extended-release (SR) capsules. Swallow them whole. They are specially formulated to release the medication slowly in the body.

What should I discuss with my healthcare provider before taking Cardene SR (nicardipine)?


Before taking nicardipine, tell your doctor if you have


  • kidney disease;

  • liver disease; or


  • another disease of the heart or blood vessels such as sick sinus syndrome, aortic stenosis, heart failure, low blood pressure, or coronary artery disease.



You may not be able to take nicardipine, or you may require a dosage adjustment or special monitoring during treatment if you have any of the conditions listed above.


Nicardipine is in the FDA pregnancy category C. This means that it is not known whether nicardipine will be harmful to an unborn baby. Do not take this medication without first talking to your doctor if you are pregnant or could become pregnant during treatment. Nicardipine passes into breast milk and may affect a nursing infant. Do not take nicardipine without first talking to your doctor if you are breast-feeding a baby. If you are over 65 years of age, you may be more likely to experience side effects from nicardipine. Your doctor may prescribe a lower dose of this medication.

How should I take Cardene SR (nicardipine)?


Take nicardipine exactly as directed by your doctor. If you do not understand these directions, ask your pharmacist, nurse, or doctor to explain them to you.


Take each dose with a full glass of water. Do not crush, break, or chew the extended-release (SR) capsules. Swallow them whole. They are specially formulated to release the medication slowly in the body. Do not stop taking nicardipine without first talking to your doctor, even if you begin to feel better. If you stop taking the medication, your condition could become worse.

Grapefruit and grapefruit juice may interact with nicardipine. The interaction could have potentially dangerous effects. Discuss the use of grapefruit and grapefruit juice with your doctor. Do not increase or decrease the amount of grapefruit products in your diet without first talking to your doctor.


Store nicardipine at room temperature away from moisture and heat.

What happens if I miss a dose?


Take the missed dose as soon as you remember. However, if it is almost time for the next dose, skip the missed dose and take only the next regularly scheduled dose. Do not take a double dose of this medication.


What happens if I overdose?


Seek emergency medical attention.

Symptoms of a nicardipine overdose include dizziness, weakness, chest pain, shortness of breath, fainting, an unusually fast or slow heartbeat, coma, slurred speech, and confusion.


What should I avoid while taking Cardene SR (nicardipine)?


Grapefruit and grapefruit juice may interact with nicardipine. The interaction could have potentially dangerous effects. Discuss the use of grapefruit and grapefruit juice with your doctor. Do not increase or decrease the amount of grapefruit products in your diet without first talking to your doctor.


Follow any recommendations your doctor makes about diet or exercise.


Use caution when you stand or sit up from a lying position, especially if you wake up during the night. You may become dizzy when changing positions. Use alcohol cautiously. Alcohol may further lower blood pressure and increase drowsiness or dizziness while taking nicardipine.

Cardene SR (nicardipine) side effects


If you experience any of the following serious side effects, stop taking nicardipine and contact your doctor immediately or seek emergency medical treatment:

  • an allergic reaction (difficulty breathing; closing of the throat; swelling of the lips, tongue, or face; or hives);




  • unusually fast or slow heartbeats;




  • fainting or severe dizziness;




  • abnormal behavior or psychosis;




  • chest pain or worsening angina;




  • jaundice (yellowing of the skin or eyes); or




  • swelling of the legs or ankles.



Other, less serious side effects may be more likely to occur. Continue to take nicardipine and talk to your doctor if you experience



  • unusual headache, fatigue, or tiredness;




  • dizziness;




  • flushing;




  • rash;




  • insomnia;




  • vivid or abnormal dreams;




  • increased urination;




  • dry mouth;




  • nausea or constipation; or




  • nervousness or tremor.



This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.


What other drugs will affect Cardene SR (nicardipine)?


Before taking nicardipine, tell your doctor if you are taking any of the following drugs:



  • another heart medication to treat the same or another condition;




  • cimetidine (Tagamet, Tagamet HB); or




  • cyclosporine (Sandimmune, Neoral).



You may not be able to take nicardipine, or you may require a dosage adjustment or special monitoring if you are taking any of the medicines listed above.


Drugs other than those listed here may also interact with nicardipine or affect your condition. Talk to your doctor and pharmacist before taking any prescription or over-the-counter medicines, including herbal products.



More Cardene SR resources


  • Cardene SR Side Effects (in more detail)
  • Cardene SR Use in Pregnancy & Breastfeeding
  • Drug Images
  • Cardene SR Drug Interactions
  • Cardene SR Support Group
  • 0 Reviews for Cardene SR - Add your own review/rating


  • Cardene SR Prescribing Information (FDA)

  • Cardene SR Sustained-Release Capsules MedFacts Consumer Leaflet (Wolters Kluwer)

  • Cardene SR Advanced Consumer (Micromedex) - Includes Dosage Information

  • Cardene Prescribing Information (FDA)

  • Cardene Monograph (AHFS DI)

  • Cardene MedFacts Consumer Leaflet (Wolters Kluwer)

  • Cardene IV Advanced Consumer (Micromedex) - Includes Dosage Information

  • Cardene IV MedFacts Consumer Leaflet (Wolters Kluwer)

  • Nicardipine Prescribing Information (FDA)



Compare Cardene SR with other medications


  • Angina Pectoris Prophylaxis
  • Heart Failure
  • High Blood Pressure


Where can I get more information?


  • Your pharmacist can provide more information about nicardipine.

See also: Cardene SR side effects (in more detail)


Nevirapine Extended-Release Tablets


Pronunciation: ne-VIR-a-peen
Generic Name: Nevirapine
Brand Name: Viramune XR

Severe and sometimes fatal liver problems have occurred in patients taking Nevirapine Extended-Release Tablets. This may occur in men and women, but the risk may be greater in women and in patients with a high CD4 cell count at the start of treatment. Certain pregnant women and women with a CD4 cell count higher than 250 have the greatest risk. Liver function tests and CD4 cell counts may be performed while you use Nevirapine Extended-Release Tablets. Contact your doctor right away if you develop a rash, dark urine, yellowing of the eyes or skin, pale stools, stomach pain, nausea, loss of appetite, or unusual tiredness.


Nevirapine Extended-Release Tablets should only be used in patients who have been diagnosed with HIV. Do not use Nevirapine Extended-Release Tablets to prevent HIV infection if you have been exposed to the virus.


Nevirapine Extended-Release Tablets may cause serious and sometimes fatal skin reactions. Contact your doctor immediately if you develop a rash or red, swollen, blistered, or peeling skin.


The risk of liver and skin problems is greatest during the first 18 weeks of therapy, but these problems may occur at any time during treatment. Your doctor will check for side effects frequently during the first several months after you start Nevirapine Extended-Release Tablets. Be sure to keep all doctor and lab appointments. Take Nevirapine Extended-Release Tablets exactly as prescribed by your doctor. If you develop a liver or skin problem or if you have a severe allergic reaction to Nevirapine Extended-Release Tablets, you must not take it again.





Nevirapine Extended-Release Tablets are used for:

Treating HIV infection. It must be used along with other HIV medicines.


Nevirapine Extended-Release Tablets are a nonnucleoside reverse transcriptase inhibitor (NNRTI). It works by blocking the growth of HIV.


Do NOT use Nevirapine Extended-Release Tablets if:


  • you are allergic to any ingredient in Nevirapine Extended-Release Tablets

  • you have moderate to severe liver problems

  • you have had a serious liver or skin reaction while taking Nevirapine Extended-Release Tablets

  • you are taking another medicine that contains nevirapine

  • you are taking efavirenz, certain HIV protease inhibitors (eg, atazanavir, fosamprenavir, lopinavir/ritonavir), itraconazole, ketoconazole, lurasidone, St. John's wort, or rifampin

  • you have not been diagnosed with HIV

Contact your doctor or health care provider right away if any of these apply to you.



Before using Nevirapine Extended-Release Tablets:


Some medical conditions may interact with Nevirapine Extended-Release Tablets. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:


  • if you are pregnant, planning to become pregnant, or are breast-feeding

  • if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement

  • if you have allergies to medicines, foods, or other substances

  • if you have liver problems (eg, cirrhosis, hepatic fibrosis, hepatitis), abnormal liver function tests, or certain skin problems (eg, growths, rash)

  • if you have kidney problems or are receiving dialysis

  • if you have a fever, a high CD4 cell count, or an abnormally high level of white blood cells

Some MEDICINES MAY INTERACT with Nevirapine Extended-Release Tablets. Tell your health care provider if you are taking any other medicines, especially any of the following:


  • Prednisone because the risk of severe skin rash may be increased

  • Fluconazole because it may increase the risk of Nevirapine Extended-Release Tablets's side effects

  • Rifampin or St. John's wort because they may decrease Nevirapine Extended-Release Tablets's effectiveness

  • Anticoagulants (eg, warfarin), HMG-CoA reductase inhibitors (eg, atorvastatin), or rifabutin because the risk of their side effects may be increased by Nevirapine Extended-Release Tablets

  • Antiarrhythmics (eg, amiodarone, disopyramide), azole antifungals (eg, itraconazole, ketoconazole), calcium channel blockers (eg, diltiazem, nifedipine, verapamil), carbamazepine, cisapride, clarithromycin, clonazepam, cyclosporine, cyclophosphamide, efavirenz, ergot alkaloids (eg, ergotamine), ethosuximide, exemestane, fentanyl, HIV protease inhibitors (eg, atazanavir, indinavir, nelfinavir), hormonal contraceptives (eg, birth control pills), lurasidone, methadone, sirolimus, tacrolimus, tyrosine kinase receptor inhibitors (eg, dasatinib), or ulipristal because their effectiveness may be decreased by Nevirapine Extended-Release Tablets

This may not be a complete list of all interactions that may occur. Ask your health care provider if Nevirapine Extended-Release Tablets may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.


How to use Nevirapine Extended-Release Tablets:


Use Nevirapine Extended-Release Tablets as directed by your doctor. Check the label on the medicine for exact dosing instructions.


  • Nevirapine Extended-Release Tablets comes with an extra patient information sheet called a Medication Guide. Read it carefully. Read it again each time you get Nevirapine Extended-Release Tablets refilled.

  • Take Nevirapine Extended-Release Tablets by mouth with or without food.

  • Swallow Nevirapine Extended-Release Tablets whole. Do not break, crush, or chew before swallowing.

  • Taking Nevirapine Extended-Release Tablets at the same time each day will help you remember to take it.

  • Continue to take Nevirapine Extended-Release Tablets even if you feel well. Do not miss any doses.

  • If you miss a dose of Nevirapine Extended-Release Tablets, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once. If you miss taking Nevirapine Extended-Release Tablets for more than 7 days, contact your doctor before you start to take it again.

Ask your health care provider any questions you may have about how to use Nevirapine Extended-Release Tablets.



Important safety information:


  • Do NOT take more than the recommended dose or use for longer than prescribed without checking with your doctor.

  • You may notice undissolved parts of Nevirapine Extended-Release Tablets in your stool. This is normal and not a cause for concern.

  • Nevirapine Extended-Release Tablets are not a cure for HIV infection. Patients may still get illnesses and infections associated with HIV. Remain under the care of your doctor.

  • When your medicine supply is low, get more from your doctor or pharmacist as soon as you can. Do not stop taking Nevirapine Extended-Release Tablets, even for a short period of time. If you do, the virus may grow resistant to the medicine and become harder to treat.

  • Nevirapine Extended-Release Tablets does not stop the spread of HIV to others through blood or sexual contact. Use barrier methods of birth control (eg, condoms) if you have HIV infection. Do not share needles, injection supplies, or items like toothbrushes or razors.

  • Changes in body fat (eg, an increased amount of fat in the upper back, neck, breast, and trunk, and loss of fat from the legs, arms, and face) may occur in some patients taking Nevirapine Extended-Release Tablets. The cause and long-term effects of these changes are unknown. Discuss any concerns with your doctor.

  • Nevirapine Extended-Release Tablets may improve immune system function. This may reveal hidden infections in some patients. Tell your doctor right away if you notice symptoms of infection (eg, fever, sore throat, weakness, cough, shortness of breath) after you start Nevirapine Extended-Release Tablets.

  • Hormonal birth control (eg, birth control pills) may not work as well while you are using Nevirapine Extended-Release Tablets. To prevent pregnancy, use an extra form of birth control (eg, condoms).

  • Lab tests, including liver and heart function, complete blood cell counts, and CD4 cell counts, may be performed while you use Nevirapine Extended-Release Tablets. These tests may be used to monitor your condition or check for side effects. Be sure to keep all doctor and lab appointments.

  • Nevirapine Extended-Release Tablets should not be used in CHILDREN; safety and effectiveness in children have not been confirmed.

  • PREGNANCY and BREAST-FEEDING: If you become pregnant, contact your doctor. You will need to discuss the benefits and risks of using Nevirapine Extended-Release Tablets while you are pregnant. Nevirapine Extended-Release Tablets are found in breast milk. Mothers infected with HIV should not breast-feed. There is a risk of passing the HIV infection or Nevirapine Extended-Release Tablets to the baby.


Possible side effects of Nevirapine Extended-Release Tablets:


All medicines may cause side effects, but many people have no, or minor, side effects. No COMMON side effects have been reported with Nevirapine Extended-Release Tablets. Seek medical attention right away if any of these SEVERE side effects occur:



Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); change in the amount of urine produced; eye irritation, pain, redness, or swelling; fever, chills, or sore throat; general feeling of being unwell; mouth sores; muscle or joint aches or pain; red, swollen, peeling, or blistered skin (with or without fever); swollen lymph glands; symptoms of liver problems (eg, yellowing of the skin or eyes; dark urine; loss of appetite; pale stools; severe, persistent, or unusual nausea or stomach pain); unusual tiredness or weakness.



This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.


See also: Nevirapine side effects (in more detail)


If OVERDOSE is suspected:


Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately. Symptoms may include dizziness; fever; nausea; rash; severe or persistent headache; swelling; trouble breathing; trouble sleeping; unexplained weight loss; unusual tiredness; vomiting.


Proper storage of Nevirapine Extended-Release Tablets:

Store Nevirapine Extended-Release Tablets at 77 degrees F (25 degrees C). Brief storage at temperatures between 59 and 86 degrees F (15 and 30 degrees C) is permitted. Store in a tightly closed container. Store away from heat, moisture, and light. Do not store in the bathroom. Keep Nevirapine Extended-Release Tablets out of the reach of children and away from pets.


General information:


  • If you have any questions about Nevirapine Extended-Release Tablets, please talk with your doctor, pharmacist, or other health care provider.

  • Nevirapine Extended-Release Tablets are to be used only by the patient for whom it is prescribed. Do not share it with other people.

  • If your symptoms do not improve or if they become worse, check with your doctor.

  • Check with your pharmacist about how to dispose of unused medicine.

This information is a summary only. It does not contain all information about Nevirapine Extended-Release Tablets. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.



Issue Date: February 1, 2012

Database Edition 12.1.1.002

Copyright © 2012 Wolters Kluwer Health, Inc.

More Nevirapine resources


  • Nevirapine Side Effects (in more detail)
  • Nevirapine Dosage
  • Nevirapine Use in Pregnancy & Breastfeeding
  • Nevirapine Drug Interactions
  • Nevirapine Support Group
  • 1 Review for Nevirapine - Add your own review/rating


Compare Nevirapine with other medications


  • HIV Infection
  • Reduction of Perinatal Transmission of HIV

Wednesday, 8 August 2012

Levetiracetam 100 mg / ml oral solution





1. Name Of The Medicinal Product



Levetiracetam 100 mg/ml oral solution


2. Qualitative And Quantitative Composition



Each ml contains 100 mg levetiracetam



Each ml contains 2.7 mg of methyl parahydroxybenzoate (E218), 0.3 mg of propyl parahydroxybenzoate (E216) and 300 mg of maltitol liquid.



For a full list of excipients, see section 6.1.



3. Pharmaceutical Form



Oral solution.



Clear and colourless solution.



4. Clinical Particulars



4.1 Therapeutic Indications



Levetiracetam is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalisation in patients from 16 years of age with newly diagnosed epilepsy.



Levetiracetam is indicated as adjunctive therapy



• in the treatment of partial onset seizures with or without secondary generalisation in adults, children and infants from 1 month of age with epilepsy.



• in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy.



• in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with Idiopathic Generalised Epilepsy.



4.2 Posology And Method Of Administration



Posology



Monotherapy for adults and adolescents from 16 years of age



The recommended starting dose is 250 mg twice daily which should be increased to an initial therapeutic dose of 500 mg twice daily after two weeks. The dose can be further increased by 250 mg twice daily every two weeks depending upon the clinical response. The maximum dose is 1500 mg twice daily.



Add-on therapy for adults (



The initial therapeutic dose is 500 mg twice daily. This dose can be started on the first day of treatment.



Depending upon the clinical response and tolerability, the daily dose can be increased up to 1,500 mg twice daily. Dose changes can be made in 500 mg twice daily increases or decreases every two to four weeks.



Special populations



Elderly (65 years and older)



Adjustment of the dose is recommended in elderly patients with compromised renal function (see "Patients with renal impairment" below).



Renal impairment



The daily dose must be individualised according to renal function.



For adult patients, refer to the following table and adjust the dose as indicated. To use this dosing table, an estimate of the patient's creatinine clearance (CLcr) in ml/min is needed. The CLcr in ml/min may be estimated from serum creatinine (mg/dl) determination, for adults and adolescents weighting 50 kg or more, the following formula:





Then CLcr is adjusted for body surface area (BSA) as follows:





Dosing adjustment for adult and adolescents patients weighing more than 50 kg with impaired renal function






















Group




Creatinine clearance



(ml/min/1.73m2)




Dosage and frequency




Normal




> 80




500 to 1,500 mg twice daily




Mild




50-79




500 to 1,000 mg twice daily




Moderate




30-49




250 to 750 mg twice daily




Severe




< 30




250 to 500 mg twice daily




End-stage renal disease patients undergoing dialysis (1)




-




500 to 1,000 mg once daily (2)



(1) A 750 mg loading dose is recommended on the first day of treatment with levetiracetam.



(2) Following dialysis, a 250 to 500 mg supplemental dose is recommended.



For children with renal impairment, levetiracetam dose needs to be adjusted based on the renal function as levetiracetam clearance is related to renal function. This recommendation is based on a study in adult renally impaired patients.



The CLcr in ml/min/1.73 m2 may be estimated from serum creatinine (mg/dl) determination using, for young adolescents, children and infants, using the following formula (Schwartz formula):





ks= 0.45 in Term infants to 1 year old; ks= 0.55 in Children to less than 13 years; ks= 0.7 in adolescent male



Dosing adjustment for infants, children and adolescents patients weighing less than 50 kg with impaired renal function
































Group




Creatinine clearance



(ml/min/1.73m2)




Dosage frequency


 


Infants 1 to less than 6 months




Infants 6 to 23 months, children and adolescents weighing less than 50 kg


  


Normal




> 80




7 to 21 mg/kg (0.07 to 0.21 ml/kg) twice daily




10 to 30 mg/kg (0.10 to 0.30 ml/kg) twice daily




Mild




50-79




7 to 14 mg/kg (0.07 to 0.14 ml/kg) twice daily




10 to 20 mg/kg (0.10 to 0.20 ml/kg) twice daily




Moderate




30-49




3.5 to 10.5 mg/kg (0.035 to 0.105 ml/kg) twice daily




5 to 15 mg/kg (0.05 to 0.15 ml/kg) twice daily




Severe




< 30




3.5 to 7 mg/kg (0.035 to 0.07 ml/kg) twice daily




5 to 10 mg/kg (0.05 to 0.10 ml/kg) twice daily




End-stage renal disease patients undergoing dialysis



 


7 to 14 mg/kg (0.07 to 0.14 ml/kg) once daily (1) (3)




10 to 20 mg/kg (0.10 to 0.20 ml/kg) once daily (2) (4)



(1) A 10.5 mg/kg (0.105 ml/kg) loading dose is recommended on the first day of treatment with levetiracetam.



(2) A 15 mg/kg (0.15 ml/kg) loading dose is recommended on the first day of treatment with levetiracetam.



(3) Following dialysis, a 3.5 to 7 mg/kg (0.035 to 0.07 ml/kg) supplemental dose is recommended.



(4) Following dialysis, a 5 to 10 mg/kg (0.05 to 0.10 ml/kg) supplemental dose is recommended.



Hepatic impairment



No dose adjustment is needed in patients with mild to moderate hepatic impairment. In patients with severe hepatic impairment, the creatinine clearance may underestimate the renal insufficiency. Therefore a 50 % reduction of the daily maintenance dose is recommended when the creatinine clearance is < 60 ml/min/1.73 m2.



Paediatric population



The physician should prescribe the most appropriate pharmaceutical form, presentation and strength according to weight and dose.



Monotherapy



The safety and efficacy of levetiracetam in children and adolescents below 16 years as monotherapy treatment have not been established.



There are no data available.



Add-on therapy for infants aged 6 to 23 months, children (2 to 11 years) and adolescents (12 to 17 years) weighing less than 50 kg



The initial therapeutic dose is 10 mg/kg twice daily.



Depending upon the clinical response and tolerability, the dose can be increased up to 30 mg/kg twice daily. Dose changes should not exceed increases or decreases of 10 mg/kg twice daily every two weeks. The lowest effective dose should be used.



Dosage in children 50 kg or greater is the same as in adults.



Dosage recommendations for infants from 6 months of age, children and adolescents:

























Weight




Starting dose:



10 mg/kg twice daily




Maximum dose:



30 mg/kg twice daily




6 kg (1)




60 mg (0.6 mL) twice daily




180 mg (1.8 mL) twice daily




10 kg (1)




100 mg (1 mL) twice daily




300 mg (3 mL) twice daily




15 kg (1)




150 mg (1.5 mL) twice daily




450 mg (4.5 mL) twice daily




20 kg (1)




200 mg (2 mL) twice daily




600 mg (6 mL) twice daily




25 kg




250 mg twice daily




750 mg twice daily




From 50 kg (2)




500 mg twice daily




1,500 mg twice daily



(1) Children 20 kg or less should preferably start the treatment with levetiracetam 100 mg/ml oral solution.



(2) Dosage in children and adolescents 50 kg or more is the same as in adults.



Add-on therapy for infants from 1 month to less than 6 months



The initial therapeutic dose is 7 mg/kg twice daily.



Depending upon the clinical response and tolerability, the dose can be increased up to 21 mg/kg twice daily. Dose changes should not exceed increases or decreases of 7 mg/kg twice daily every two weeks.



The lowest effective dose should be used.



Infants should start the treatment with levetiracetam 100 mg/ml oral solution.



Dose recommendations for infants less than 6 months:
















Weight




Starting dose:



7 mg/kg twice daily




Maximum dose:



21 mg/kg twice daily




4 kg




28 mg (0.3 mL) twice daily




84 mg (0.85 mL) twice daily




5 kg




35 mg (0.35 mL) twice daily




105 mg (1.05 mL) twice daily




7 kg




49 mg (0.5 mL)twice daily




147 mg (1.5 mL) twice daily



The physician should prescribe the most appropriate pharmaceutical form, presentation and strength according to weight and dose.



Three presentations are available:



- A 300 ml bottle with graduated oral syringe containing up to 1000 mg levetiracetam (corresponding to 10 ml) with a graduation every 0.25 ml (corresponding to 25 mg).



- A 150 ml bottle with graduated oral syringe containing up to 300 mg levetiracetam (corresponding to 3 ml) with a graduation every 0.1 ml (corresponding to 10 mg).



In order to ensure the accuracy of the dosing, the smaller bottle (150 ml) and syringe graduated from 0.1 to 3 ml per graduation of 0.1 ml should be prescribed for infants older than 6 months and young children.



- A 150 ml bottle with graduated oral syringe containing up to 100 mg levetiracetam (corresponding to 1 ml) with a graduation every 0.05 ml (corresponding to 5 mg).



In order to ensure the accuracy of the dosing, the smaller bottle (150 ml) and syringe graduated from 0.05 to 1 ml per graduation of 0.05 ml should be prescribed for infants less than 6 months.



Method of administration



The oral solution may be diluted in a glass of water and may be taken with or without food. A graduated oral syringe, an adaptor for the syringe and instructions for use in the package leaflet are provided with levetiracetam. The daily dose is administered in two equally divided doses.



4.3 Contraindications



Hypersensitivity to levetiracetam or other pyrrolidone derivatives or any of the excipients.



4.4 Special Warnings And Precautions For Use



Discontinuation



In accordance with current clinical practice, if levetiracetam has to be discontinued it is recommended to withdraw it gradually (e.g. in adults: 500 mg decreases twice daily every two to four weeks; in infants older than 6 months, children and adolescents weighting less than 50 kg: dose decrease should not exceed 10 mg/kg twice daily every two weeks; in infants (less than 6 months): dose decrease should not exceed 7 mg/ kg twice daily every two weeks).



Renal insufficiency



The administration of levetiracetam to patients with renal impairment may require dose adjustment. In patients with severely impaired hepatic function, assessment of renal function is recommended before dose selection (see section 4.2).



Suicide



Suicide, suicide attempt, suicidal ideation and behaviour have been reported in patients treated with anti-epileptic agents (including levetiracetam). A meta-analysis of randomized placebo-controlled trials of anti-epileptic drugs has shown a small increased risk of suicidal thoughts and behaviour. The mechanism of this risk is not known.



Therefore patients should be monitored for signs of depression and/or suicidal ideation and behaviours and appropriate treatment should be considered. Patients (and caregivers of patients) should be advised to seek medical advice should signs of depression and/or suicidal ideation or behaviour emerge.



Paediatric population



Available data in children did not suggest impact on growth and puberty. However, long term effects on learning, intelligence, growth, endocrine function, puberty and childbearing potential in children remain unknown.



The safety and efficacy of levetiracetam has not been thoroughly assessed in infants aged less than 1 year. Only 35 infants aged less than 1 year have been exposed in clinical studies of which only 13 were aged < 6 months.



Excipients



Levetiracetam 100 mg/ml oral solution includes methyl parahydroxybenzoate (E218) and propyl parahydroxybenzoate (E216) which may cause allergic reactions (possibly delayed). It also includes maltitol liquid; patients with rare hereditary problems of fructose intolerance should not take this medicine.



4.5 Interaction With Other Medicinal Products And Other Forms Of Interaction



Antiepileptic medicinal products



Pre-marketing data from clinical studies conducted in adults indicate that levetiracetam did not influence the serum concentrations of existing antiepileptic medicinal products (phenytoin, carbamazepine, valproic acid, phenobarbital, lamotrigine, gabapentin and primidone) and that these antiepileptic medicinal products did not influence the pharmacokinetics of levetiracetam.



As in adults, there is no evidence of clinically significant medicinal product interactions in paediatric patients receiving up to 60 mg/kg/day levetiracetam.



A retrospective assessment of pharmacokinetic interactions in children and adolescents with epilepsy (4 to 17 years) confirmed that adjunctive therapy with orally administered levetiracetam did not influence the steady-state serum concentrations of concomitantly administered carbamazepine and valproate. However, data suggested a 20% higher levetiracetam clearance in children taking enzyme-inducing antiepileptic medicinal products. Dosage adjustment is not required.



Probenecid



Probenecid (500 mg four times daily), a renal tubular secretion blocking agent, has been shown to inhibit the renal clearance of the primary metabolite but not of levetiracetam. Nevertheless, the concentration of this metabolite remains low. It is expected that other medicinal products excreted by active tubular secretion could also reduce the renal clearance of the metabolite. The effect of levetiracetam on probenecid was not studied and the effect of levetiracetam on other actively secreted medicinal products, e.g. NSAIDs, sulfonamides and methotrexate, is unknown.



Oral contraceptives and other pharmacokinetics interactions



Levetiracetam 1,000 mg daily did not influence the pharmacokinetics of oral contraceptives (ethinyl-estradiol and levonorgestrel); endocrine parameters (luteinizing hormone and progesterone) were not modified. levetiracetam 2,000 mg daily did not influence the pharmacokinetics of digoxin and warfarin; prothrombin times were not modified. Co-administration with digoxin, oral contraceptives and warfarin did not influence the pharmacokinetics of levetiracetam.



Antacids



No data on the influence of antacids on the absorption of levetiracetam are available.



Food and alcohol



The extent of absorption of levetiracetam was not altered by food, but the rate of absorption was slightly reduced.



No data on the interaction of levetiracetam with alcohol are available.



4.6 Pregnancy And Lactation



Pregnancy



There are no adequate data from the use of levetiracetam in pregnant women. Studies in animals have shown reproductive toxicity (see section 5.3). The potential risk for human is unknown. Levetiracetam is not recommended during pregnancy and in women of childbearing potential not using contraception unless clearly necessary.



As with other antiepileptic drugs, physiological changes during pregnancy may affect levetiracetam concentration. Decrease in levetiracetam plasma concentrations has been observed during pregnancy. This decrease is more pronounced during the third trimester (up to 60% of baseline concentration before pregnancy). Appropriate clinical management of pregnant women treated with levetiracetam should be ensured. Discontinuation of antiepileptic treatments may result in exacerbation of the disease which could be harmful to the mother and the foetus.



Breastfeeding



Levetiracetam is excreted in human breast milk. Therefore, breast-feeding is not recommended. However, if levetiracetam treatment is needed during breastfeeding, the benefit/risk of the treatment should be weighed considering the importance of breastfeeding.



Fertility



No impact on fertility was detected in animal studies (see section 5.3). No clinical data are available, potential risk for human is unknown.



4.7 Effects On Ability To Drive And Use Machines



No studies on the effects on the ability to drive and use machines have been performed. Due to possible different individual sensitivity, some patients might experience somnolence or other central nervous system related symptoms, especially at the beginning of treatment or following a dose increase. Therefore, caution is recommended in those patients when performing skilled tasks, e.g. driving vehicles or operating machinery. Patients are advised not to drive or use machines until it is established that their ability to perform such activities is not affected.



4.8 Undesirable Effects



Summary of the safety profile



Pooled safety data from clinical studies conducted with levetiracetam oral formulations in adult patients with partial onset seizures showed that 46.4 % of the patients in the levetiracetam group and 42.2 % of the patients in the placebo group experienced undesirable effects. Serious undesirable effects were experienced in 2.4% of the patients in the levetiracetam and 2.0% of the patients in the placebo groups. The most commonly reported undesirable effects were somnolence, asthenia and dizziness. In the pooled safety analysis, there was no clear dose-response relationship but incidence and severity of the central nervous system related undesirable effects decreased over time.



In monotherapy 49.8 % of the subjects experienced at least one drug related undesirable effect. The most frequently reported undesirable effects were fatigue and somnolence.



A study conducted in adults and adolescents with myoclonic seizures (12 to 65 years) showed that 33.3% of the patients in the levetiracetam group and 30.0% of the patients in the placebo group experienced undesirable effects that were judged to be related to treatment. The most commonly reported undesirable effects were headache and somnolence. The incidence of undesirable effects in patients with myoclonic seizures was lower than that in adult patients with partial onset seizures (33.3% versus 46.4%).



A study conducted in adults and children (4 to 65 years) with idiopathic generalised epilepsy with primary generalised tonic-clonic seizures showed that 39.2 % of the patients in the Levetiracetam group and 29.8 % of the patients in the placebo group experienced undesirable effects that were judged to be related to treatment. The most commonly reported undesirable effect was fatigue.



An increase in seizure frequency of more than 25 % was reported in 14 % of levetiracetam treated adult and paediatric patients (4 to 16 years of age) with partial onset seizures, whereas it was reported in 26 % and 21 % of placebo treated adult and paediatric patients, respectively.



When Levetiracetam was used to treat primary generalised tonic-clonic seizures in adults and adolescents with idiopathic generalised epilepsy, there was no effect on the frequency of absences.



Tabulated list of adverse reactions



Adverse reactions reported in clinical studies (adults, adolescents, children and infants > 1 month) or from post-marketing experience are listed in the following table per System Organ Class and per frequency. For clinical trials, the frequency is defined as follows: very common (



- Infections and infestations



Common: infection, nasopharyngitis



- Blood and lymphatic system disorders



Common: thrombocytopenia



Post-marketing experience: leukopenia, neutropenia, pancytopenia (with bone marrow suppression identified in some of the cases).



- Metabolism and nutrition disorders



Common: anorexia, weight increase.



The risk of anorexia is higher when topiramate is coadministered with levetiracetam.



Post-marketing experience: weight loss



- Psychiatric disorders



Common: agitation, depression, emotional lability/mood swings, hostility/aggression, insomnia, nervousness/irritability, personality disorders, thinking abnormal



Post-marketing experience: abnormal behaviour, anger, anxiety, confusion, hallucination, psychotic disorder, suicide, suicide attempt and suicidal ideation



- Nervous system disorders



Very common: somnolence



Common: amnesia, ataxia, convulsion, dizziness, headache, hyperkinesia, tremor, balance disorder, disturbance in attention, memory impairment.



Post-marketing experience: paraesthesia



- Eye disorders



Common: diplopia, vision blurred



- Ear and labyrinth disorders



Common: vertigo



- Respiratory, thoracic and mediastinal disorders



Common: cough increased



- Gastrointestinal disorders



Common: abdominal pain, diarrhoea, dyspepsia, nausea, vomiting



Post-marketing experience: pancreatitis



- Hepatobiliary disorders:



Post-marketing experience: hepatic failure, hepatitis, liver function test abnormal



- Skin and subcutaneous tissue disorders



Common: rash, eczema, pruritus



Post-marketing experience: alopecia: in several cases, recovery was observed when levetiracetam was discontinued.



- Musculoskeletal and connective tissue disorders



Common: myalgia



- General disorders and administration site conditions



Very common: asthenia/fatigue.



- Injury, poisoning and procedural complications



Common: accidental injury



Description of selected adverse reactions



The risk of anorexia is higher when topiramate is coadministered with levetiracetam.



In several cases of alopecia, recovery was observed when levetiracetam was discontinued.



Paediatric population



A study conducted in paediatric patients (4 to 16 years) with partial onset seizures showed that 55.4 % of the patients in the levetiracetam group and 40.2 % of the patients in the placebo group experienced undesirable effects. Serious undesirable effects were experienced in 0.0 % of the patients in the levetiracetam group and 1.0 % of the patients in the placebo group. The most commonly reported undesirable effects were somnolence, hostility, nervousness, emotional lability, agitation, anorexia, asthenia and headache in the paediatric population. Safety results in paediatric patients were consistent with the safety profile of levetiracetam in adults except for behavioural and psychiatric adverse events which were more common in children than in adults (38.6% versus 18.6%). However, the relative risk was similar in children as compared to adults.



A study conducted in paediatric patients (1 month to less than 4 years) with partial onset seizures showed that 21.7 % of the patients in the levetiracetam group and 7.1 % of the patients in the placebo group experienced undesirable effects. No Serious undesirable effects were experienced in patients in the levetiracetam or Placebo group. During the long-term follow-up study N01148, the most frequent drug-related treatment-emergent adverse events in the 1m - <4y group were irritability (7.9%), convulsion (7.2%), somnolence (6.6%), psychomotor hyperactivity (3.3%), sleep disorder (3.3%), and aggression (3.3%). Safety results in paediatric patients were consistent with the safety profile of levetiracetam in older children aged 4 to 16 years.



A double-blind, placebo-controlled paediatric safety study with a non-inferiority design has assessed the cognitive and neuropsychological effects of levetiracetam in children 4 to 16 years of age with partial onset seizures. It was concluded that levetiracetam was not different (non inferior) from placebo with regard to the change from baseline of the Leiter-R Attention and Memory, Memory Screen Composite score in the per-protocol population. Results related to behavioural and emotional functioning indicated a worsening in levetiracetam treated patients on aggressive behaviour as measured in a standardized and systematic way using a validated instrument (CBCL - Achenbach Child Behaviour Checklist). However subjects, who took levetiracetam in the long-term open label follow-up study, did not experience a worsening, on average, in their behavioural and emotional functioning; in particular measures of aggressive behaviour were not worse than baseline.



4.9 Overdose



Symptoms



Somnolence, agitation, aggression, depressed level of consciousness, respiratory depression and coma were observed with levetiracetam overdoses.



Management of overdose



After an acute overdose, the stomach may be emptied by gastric lavage or by induction of emesis. There is no specific antidote for levetiracetam. Treatment of an overdose will be symptomatic and may include haemodialysis. The dialyser extraction efficiency is 60 % for levetiracetam and 74 % for the primary metabolite.



5. Pharmacological Properties



5.1 Pharmacodynamic Properties



Pharmacotherapeutic group: antiepileptics, other antiepileptics, ATC code: N03AX14. The active substance, levetiracetam, is a pyrrolidone derivative (S-enantiomer of α-ethyl-2-oxo-1-pyrrolidine acetamide), chemically unrelated to existing antiepileptic active substances.



Mechanism of action



The mechanism of action of levetiracetam still remains to be fully elucidated but appears to be different from the mechanisms of current antiepileptic medicinal products. In vitro and in vivo experiments suggest that levetiracetam does not alter basic cell characteristics and normal neurotransmission.



In vitro studies show that levetiracetam affects intraneuronal Ca2+ levels by partial inhibition of N-type Ca2+ currents and by reducing the release of Ca2+ from intraneuronal stores. In addition it partially reverses the reductions in GABA- and glycine-gated currents induced by zinc and β-carbolines. Furthermore, levetiracetam has been shown in in vitro studies to bind to a specific site in rodent brain tissue. This binding site is the synaptic vesicle protein 2A, believed to be involved in vesicle fusion and neurotransmitter exocytosis. Levetiracetam and related analogs show a rank order of affinity for binding to the synaptic vesicle protein 2A which correlates with the potency of their anti-seizure protection in the mouse audiogenic model of epilepsy. This finding suggests that the interaction between levetiracetam and the synaptic vesicle protein 2A seems to contribute to the antiepileptic mechanism of action of the medicinal product.



Pharmacodynamic effects



Levetiracetam induces seizure protection in a broad range of animal models of partial and primary generalised seizures without having a pro-convulsant effect. The primary metabolite is inactive.



In man, an activity in both partial and generalised epilepsy conditions (epileptiform discharge/photoparoxysmal response) has confirmed the broad spectrum pharmacological profile of levetiracetam.



Clinical experience



Adjunctive therapy in the treatment of partial onset seizures with or without secondary generalisation in adults, adolescents, children and infants from 1 month of age with epilepsy:



In adults, levetiracetam efficacy has been demonstrated in 3 double-blind, placebo-controlled studies at 1000 mg, 2000 mg, or 3000 mg/day, given in 2 divided doses, with a treatment duration of up to 18 weeks. In a pooled analysis, the percentage of patients who achieved 50% or greater reduction from baseline in the partial onset seizure frequency per week at stable dose (12/14 weeks) was of 27.7%, 31.6% and 41.3% for patients on 1000, 2000 or 3000 mg levetiracetam respectively and of 12.6% for patients on placebo.



Paediatric population



In paediatric patients (4 to 16 years of age), levetiracetam efficacy was established in a double-blind, placebo-controlled study, which included 198 patients and had a treatment duration of 14 weeks. In this study, the patients received levetiracetam as a fixed dose of 60 mg/kg/day (with twice a day dosing).



44.6% of the levetiracetam treated patients and 19.6% of the patients on placebo had a 50% or greater reduction from baseline in the partial onset seizure frequency per week. With continued long-term treatment, 11.4% of the patients were seizure-free for at least 6 months and 7.2% were seizure-free for at least 1 year.



In paediatric patients (1 month to less than 4 years of age), levetiracetam efficacy was established in a double-blind, placebo-controlled study, which included 116 patients and had a treatment duration of 5 days. In this study, patients were prescribed 20 mg/kg, 25 mg/kg, 40 mg/kg or 50 mg/kg daily dose of oral solution based on their age titration schedule. A dose of 20 mg/kg/day titrating to 40 mg/kg/day for infants one month to less than six month and a dose of 25 mg/kg/day titrating to 50 mg/kg/day for infants and children 6 month to less than 4 years old, was use in this study. The total daily dose was administered b.i.d.



The primary measure of effectiveness was the responder rate (percent of patients with



Monotherapy in the treatment of partial onset seizures with or without secondary generalisation in patients from 16 years of age with newly diagnosed epilepsy.



Efficacy of levetiracetam as monotherapy was established in a double-blind, parallel group, non-inferiority comparison to carbamazepine controlled release (CR) in 576 patients 16 years of age or older with newly or recently diagnosed epilepsy. The patients had to present with unprovoked partial seizures or with generalized tonic-clonic seizures only. The patients were randomized to carbamazepine CR 400 - 1200 mg/day or levetiracetam 1000 - 3000 mg/day, the duration of the treatment was up to 121 weeks depending on the response.



Six-month seizure freedom was achieved in 73.0% of levetiracetam-treated patients and 72.8% of carbamazepine-CR treated patients; the adjusted absolute difference between treatments was 0.2% (95% CI: -7.8 8.2). More than half of the subjects remained seizure free for 12 months (56.6% and 58.5% of subjects on levetiracetam and on carbamazepine CR respectively).



In a study reflecting clinical practice, the concomitant antiepileptic medication could be withdrawn in a limited number of patients who responded to levetiracetam adjunctive therapy (36 adult patients out of 69).



Adjunctive therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy.



Levetiracetam efficacy was established in a double-blind, placebo-controlled study of 16 weeks duration, in patients 12 years of age and older suffering from idiopathic generalized epilepsy with myoclonic seizures in different syndromes. The majority of patients presented with juvenile myoclonic epilepsy.



In this study, levetiracetam, dose was 3000 mg/day given in 2 divided doses.



58.3% of the levetiracetam treated patients and 23.3% of the patients on placebo had at least a 50% reduction in myoclonic seizure days per week. With continued long-term treatment, 28.6% of the patients were free of myoclonic seizures for at least 6 months and 21.0% were free of myoclonic seizures for at least 1 year.



Adjunctive therapy in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy.



Levetiracetam efficacy was established in a 24-week double-blind, placebo-controlled study which included adults, adolescents and a limited number of children suffering from idiopathic generalized epilepsy with primary generalized tonic-clonic (PGTC) seizures in different syndromes (juvenile myoclonic epilepsy, juvenile absence epilepsy, childhood absence epilepsy, or epilepsy with Grand Mal seizures on awakening). In this study, levetiracetam dose was 3000 mg/day for adults and adolescents or 60 mg/kg/day for children, given in 2 divided doses.



72.2% of the levetiracetam treated patients and 45.2% of the patients on placebo had a 50% or greater decrease in the frequency of PGTC seizures per week. With continued long-term treatment, 47.4% of the patients were free of tonic-clonic seizures for at least 6 months and 31.5% were free of tonic-clonic seizures for at least 1 year.



5.2 Pharmacokinetic Properties



Levetiracetam is a highly soluble and permeable compound. The pharmacokinetic profile is linear with low intra- and inter-subject variability. There is no modification of the clearance after repeated administration. There is no evidence for any relevant gender, race or circadian variability. The pharmacokinetic profile is comparable in healthy volunteers and in patients with epilepsy.



Due to its complete and linear absorption, plasma levels can be predicted from the oral dose of levetiracetam expressed as mg/kg bodyweight. Therefore there is no need for plasma level monitoring of levetiracetam.



A significant correlation between saliva and plasma concentrations has been shown in adults and children (ratio of saliva/plasma concentrations ranged from 1 to 1.7 for oral tablet formulation and after 4 hours post-dose for oral solution formulation).



Adults and adolescents



Absorption



Levetiracetam is rapidly absorbed after oral administration. Oral absolute bioavailability is close to 100 %.



Peak plasma concentrations (Cmax) are achieved at 1.3 hours after dosing. Steady-state is achieved after two days of a twice daily administration schedule.



Peak concentrations (Cmax) are typically 31 and 43 µg/ml following a single 1,000 mg dose and repeated 1,000 mg twice daily dose, respectively.



The extent of absorption is dose-independent and is not altered by food.



Distribution



No tissue distribution data are available in humans.



Neither levetiracetam nor its primary metabolite are significantly bound to plasma proteins (< 10 %). The volume of distribution of levetiracetam is approximately 0.5 to 0.7 l/kg, a value close to the total body water volume.



Biotransformation



Levetiracetam is not extensively metabolised in humans. The major metabolic pathway (24 % of the dose) is an enzymatic hydrolysis of the acetamide group. Production of the primary metabolite, ucb L057, is not supported by liver cytochrome P450 isoforms. Hydrolysis of the acetamide group was measurable in a large number of tissues including blood cells. The metabolite ucb L057 is pharmacologically inactive.



Two minor metabolites were also identified. One was obtained by hydroxylation of the pyrrolidone ring (1.6 % of the dose) and the other one by opening of the pyrrolidone ring (0.9 % of the dose). Other unidentified components accounted only for 0.6 % of the dose.



No enantiomeric interconversion was evidenced in vivo for either levetiracetam or its primary metabolite.



In vitro, levetiracetam and its primary metabolite have been shown not to inhibit the major human liver cytochrome P450 isoforms (CYP3A4, 2A6, 2C9, 2C19, 2D6, 2E1 and 1A2), glucuronyl transferase (UGT1A1 and UGT1A6) and epoxide hydroxylase activities. In addition, levetiracetam does not affect the in vitro glucuronidation of valproic acid.



In human hepatocytes in culture, levetiracetam had little or no effect on CYP1A2, SULT1E1 or UGT1A1. Levetiracetam caused mild induction of CYP2B6 and CYP3A4. The in vitro data and in vivo interaction data on oral contraceptives, digoxin and warfarin indicate that no significant enzyme induction is expected in vivo. Therefore, the interaction of levetiracetam with other substances, or vice versa, is unlikely.



Elimination



The plasma half-life in adults was 7±1 hours and did not vary either with dose, route of administration or repeated administration. The mean total body clearance was 0.96 ml/min/kg.



The major route of excretion was via urine, accounting for a mean 95 % of the dose (approximately 93 % of the dose was excreted within 48 hours). Excretion via faeces accounted for only 0.3 % of the dose.



The cumulative urinary excretion of levetiracetam and its primary metabolite accounted for 66 % and 24 % of the dose, respectively during the first 48 hours.



The renal clearance of levetiracetam and ucb L057 is 0.6 and 4.2 ml/min/kg respectively indicating that levetiracetam is excreted by glomerular filtration with subsequent tubular reabsorption and that the primary metabolite is also excreted by active tubular secretion in addition to glomerular filtration.



Levetiracetam elimination is correlated to creatinine clearance.



Elderly



In the elderly, the half-life is increased by about 40 % (10 to 11 hours). This is related to the decrease in renal function in this population (see section 4.2).



Renal impairment



The apparent body clearance of both levetiracetam and of its primary metabolite is correlated to the creatinine clearance. It is therefore recommended to adjust the maintenance daily dose of Levetiracetam, based on creatinine clearance in patients with moderate and severe renal impairment (see section 4.2).



In anuric end-stage renal disease adult subjects the half-life was approximately 25 and 3.1 hours during interdialytic and intradialytic periods, respectively.



The fractional removal of levetiracetam was 51 % during a typical 4-hour dialysis session.



Hepatic impairment



In subjects with mild and moderate hepatic impairment, there was no relevant modification of the clearance of levetiracetam. In most subjects with severe hepatic impairment, the clearance of levetiracetam was reduced by more than 50 % due to a concomitant renal impairment (see section 4.2).



Peadiatric population



Children (4 to 12 years)



Following single oral dose administration (20 mg/kg) to epileptic children (6 to 12 years), the half-life of levetiracetam was 6.0 hours. The apparent body weight adjusted clearance was approximately 30 % higher than in epileptic adults.



Following repeated oral dose administration (20 to 60 mg/kg/day) to epileptic children (4 to 12 years), levetiracetam was rapidly absorbed. Peak plasma concentration was observed 0.5 to 1.0 hour after dosing. Linear and dose proportional increases were observed for peak plasma concentrations and area under the curve. The elimination half-life was approximately 5 hours. The apparent body clearance was 1.1 ml/min/kg.



Infants and children (1 month to 4 years)



Following single dose administration (20 mg/kg) of a 100 mg/ml oral solution to epilepti

Cloderm


Generic Name: clocortolone topical (kloe KOR toe lone)

Brand Names: Cloderm


What is Cloderm (clocortolone topical)?

Clocortolone is a topical (for the skin) steroid. It reduces the actions of chemicals in the body that cause inflammation, redness, and swelling.


Clocortolone topical is used to treat the inflammation and itching caused by a number of skin conditions such as allergic reactions, eczema, and psoriasis.


Clocortolone topical may also be used for other purposes not listed in this medication guide.


What is the most important information I should know about Cloderm (clocortolone topical)?


Use this medication exactly as directed on the label, or as it has been prescribed by your doctor. Do not use the medication in larger amounts or for longer than recommended. Topical steroid medicine can be absorbed through the skin, which may cause steroid side effects throughout the body.


Do not cover treated skin areas with a bandage or other covering unless your doctor has told you to. If you are treating the diaper area of a baby, do not use plastic pants or tight-fitting diapers. Covering the skin that is treated with clocortolone topical can increase the amount of medicine your skin absorbs, which may lead to unwanted side effects. Follow your doctor's instructions. Do not use this medication on a child without a doctor's advice. Children are more likely to absorb large amounts of a topical steroid through the skin. Steroid absorption in children may cause unwanted side effects, or a delay in growth with long-term use. Talk with your doctor if you think your child is not growing at a normal rate while using this medication over a long treatment period. Contact your doctor if your condition does not improve, or if you develop signs of a bacterial, fungal, or viral skin infection.

What should I discuss with my healthcare provider before using Cloderm (clocortolone topical)?


Do not use this medication if you are allergic to clocortolone.

Before using clocortolone topical, tell your doctor if you are allergic to any drugs, or if you have any type of skin infection.


Also tell your doctor if you have diabetes. Topical steroid medicines absorbed through the skin may increase the glucose (sugar) levels in your blood or urine.


FDA pregnancy category C. This medication may be harmful to an unborn baby. Tell your doctor if you are pregnant or plan to become pregnant during treatment. It is not known whether clocortolone topical passes into breast milk or if it could harm a nursing baby. Do not use this medication without telling your doctor if you are breast-feeding a baby. Do not use this medication on a child without a doctor's advice. Children are more likely to absorb large amounts of a topical steroid through the skin. Steroid absorption in children may cause unwanted side effects, or a delay in growth with long-term use. Talk with your doctor if you think your child is not growing at a normal rate while using this medication over a long treatment period.

How should I use Cloderm (clocortolone topical)?


Use this medication exactly as directed on the label, or as it has been prescribed by your doctor. Do not use the medication in larger amounts or for longer than recommended. Topical steroid medicine can be absorbed through the skin, which may cause steroid side effects throughout the body.


Wash your hands before and after using clocortolone topical, unless you are using the medication to treat the skin on your hands.

Apply a small amount to the affected area and rub it gently into the skin. Do not use this medication over a large area of skin.


Do not cover treated skin areas with a bandage or other covering unless your doctor has told you to. If you are treating the diaper area of a baby, do not use plastic pants or tight-fitting diapers. Covering the skin that is treated with clocortolone topical can increase the amount of medicine your skin absorbs, which may lead to unwanted side effects. Follow your doctor's instructions. Contact your doctor if your condition does not improve, or if you develop signs of a bacterial, fungal, or viral skin infection. It is important to use clocortolone topical regularly to get the most benefit.

To be sure this medication is not causing harmful effects with long-term use, you may need blood tests. Do not miss any scheduled appointments.


Store clocortolone topical at room temperature away from moisture and heat. Keep from freezing.

What happens if I miss a dose?


Use the medication as soon as you remember. If it is almost time for the next dose, skip the missed dose and use the medicine at the next regularly scheduled time. Do not use extra medicine to make up the missed dose.


What happens if I overdose?


Seek emergency medical attention if you think you have used too much of this medicine.

An overdose of clocortolone is not expected to produce life-threatening symptoms. However, long-term use of high steroid doses can lead to symptoms such as thinning skin, easy bruising, changes in the shape or location of body fat (especially in your face, neck, back, and waist), increased acne or facial hair, menstrual problems, impotence, or loss of interest in sex.


What should I avoid while using Cloderm (clocortolone topical)?


Clocortolone topical should not be used to treat any skin condition your doctor has not prescribed it for.


Avoid getting this medication in your eyes. If contact does occur, rinse with water. Do not use clocortolone topical on broken or infected skin. Also avoid using this medication in open wounds.

Cloderm (clocortolone topical) side effects


Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat. Stop using this medication and call your doctor at once if you have severe irritation of any treated skin, or if you show signs of absorbing clocortolone topical through your skin, such as:

  • blurred vision, or seeing halos around lights;




  • mood changes;




  • sleep problems (insomnia);




  • weight gain, puffiness in your face; or




  • muscle weakness, feeling tired.



Less serious side effects may include:



  • mild skin itching, burning, peeling, or dryness;




  • thinning or softening of your skin;




  • skin rash or irritation around your mouth;




  • swollen hair follicles;




  • changes in color of treated skin;




  • blisters, pimples, or crusting of treated skin; or




  • stretch marks.



This is not a complete list of side effects and others may occur. Tell your doctor about any unusual or bothersome side effect. You may report side effects to FDA at 1-800-FDA-1088.


What other drugs will affect Cloderm (clocortolone topical)?


It is not likely that other drugs you take orally or inject will have an effect on topically applied clocortolone topical. But many drugs can interact with each other. Tell your doctor about all your prescription and over-the-counter medications, vitamins, minerals, herbal products, and drugs prescribed by other doctors. Do not start a new medication without telling your doctor.



More Cloderm resources


  • Cloderm Side Effects (in more detail)
  • Cloderm Use in Pregnancy & Breastfeeding
  • Cloderm Drug Interactions
  • Cloderm Support Group
  • 3 Reviews for Cloderm - Add your own review/rating


  • Cloderm Prescribing Information (FDA)

  • Cloderm MedFacts Consumer Leaflet (Wolters Kluwer)



Compare Cloderm with other medications


  • Atopic Dermatitis
  • Dermatitis
  • Eczema
  • Psoriasis


Where can I get more information?


  • Your pharmacist can provide more information about clocortolone topical.

See also: Cloderm side effects (in more detail)


Tuesday, 7 August 2012

Zavesca (miglustat) 100 mg hard capsules






Zavesca 100 mg hard capsules


Miglustat



Read all of this leaflet carefully before you start taking this medicine.


  • Keep this leaflet. You may need to read it again.

  • If you have any further questions, please ask your doctor or pharmacist.

  • This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if their symptoms are the same as yours.

  • If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.



In this leaflet:


1. What Zavesca is and what it is used for

2. Before you take Zavesca

3. How to take Zavesca

4. Possible side effects

5. How to store Zavesca

6. Further information





What Zavesca Is And What It Is Used For


Zavesca belongs to a group of medicines that affect metabolism. It is used to treat two conditions:



  • Zavesca is used to treat mild to moderate type 1 Gaucher disease.

In type 1 Gaucher disease, a substance called glucosylceramide is not removed from your body. It starts to build up in certain cells of the body’s immune system. This can result in liver and spleen enlargement, changes in the blood, and bone disease.


The usual treatment for type 1 Gaucher disease is enzyme replacement therapy. Zavesca is only used when a patient is considered unsuitable for treatment with enzyme replacement therapy.



  • Zavesca is also used to treat progressive neurological symptoms in Niemann-Pick type C disease.

If you have Niemann-Pick type C disease, fats such as glycosphingolipids build up in the cells of your brain. This can result in disturbances in neurological functions such as eye movements, balance, swallowing, and memory, and in seizures.


Zavesca works by inhibiting the enzyme called ‘glucosylceramide synthase’ which is responsible for the first step in the synthesis of most glycosphingolipids.




Before You Take Zavesca



Do not take Zavesca


  • if you are allergic (hypersensitive) to miglustat or any of the other ingredients of Zavesca. If this applies to you, tell your doctor. Don’t take Zavesca.



Take special care with Zavesca


  • if you suffer from kidney disease

  • if you suffer from liver disease

If any of these apply to you, tell your doctor before you take Zavesca.


Your doctor will perform the following tests before treatment and during treatment with Zavesca:


  • an examination to check the nerves in your arms and legs

  • measurement of vitamin B12 levels

  • monitoring growth if you are a child or adolescent with Niemann-Pick type C disease

  • monitoring of blood platelet counts if you are a patient with Niemann-Pick type C disease

The reason for these tests is that some patients have had tingling or numbness in the hands and feet, or a decrease in body weight, while taking Zavesca. The tests will help the doctor decide whether these effects are due to your disease or other existing conditions, or due to side effects of Zavesca (see section 4 for further details).


If you have diarrhoea, your doctor may ask you to change your diet to reduce your lactose and carbohydrate intake, or not to take Zavesca together with food, or to temporarily reduce your dose. In some cases the doctor may prescribe anti-diarrhoeal medicines such as loperamide. If your diarrhoea does not respond to these measures, or if you have any other abdominal complaint, consult your doctor. In such case, your doctor may decide to conduct further investigations.


Male patients should use reliable birth control methods during their treatment with Zavesca, and for 3 months after finishing treatment.




Using other medicines


Talk to your doctor if you are using Cerezyme, or other medicines containing imiglucerase, which are sometimes used at the same time as Zavesca. They may lower the amount of Zavesca in your body. Please tell your doctor or pharmacist if you are using, or have recently used, any other medicines, including medicines obtained without prescription.




Taking Zavesca with food and drink


Zavesca can be taken with or without food. You should swallow the whole capsule with a glass of water.




Pregnancy and breast-feeding


You should not use Zavesca if you are pregnant or thinking of becoming pregnant. Your doctor can give you more information. You must use effective birth control while using Zavesca. Do not breast-feed while you are using Zavesca.


Male patients should use reliable birth control methods during their treatment with Zavesca, and for 3 months after finishing treatment.


Ask your doctor or pharmacist for advice before taking any medicine.




Driving and using machines


Zavesca may make you feel dizzy. Do not drive or use any tools or machines if you feel dizzy.





How To Take Zavesca


Always take Zavesca exactly as your doctor has told you. You should check with your doctor or pharmacist if you are not sure about any of the instructions.



  • For type 1 Gaucher disease: For adults, the usual dose is one capsule (100 mg) three times a day (morning, afternoon and evening). This means a daily maximum of three capsules (300 mg).


  • For Niemann-Pick type C disease: For adults and adolescents, the usual dose is two capsules (200 mg) three times a day (morning, afternoon and evening). This means a daily maximum of six capsules (600 mg).

If you are less than 12 years old, your doctor will adjust your dose for Niemann-Pick type C disease.


If you have a problem with your kidneys you may receive a lower starting dose. Your doctor may reduce your dose, e.g., to one capsule (100 mg) once or twice a day, if you suffer from diarrhoea when taking Zavesca (see section 4). Your doctor will tell you how long your treatment will last.



To remove the capsule:



1. Separate at perforations

2. Peel back paper at arrows

3. Push product through foil


The Zavesca capsule should be swallowed whole with water.




If you take more Zavesca than you should


If you take more capsules than you were told to, consult your doctor immediately. Zavesca has been used in clinical trials at doses ten times higher than the recommended dose: this caused decreases in white blood cells and other side effects similar to those described in section 4.




If you forget to take Zavesca


Take the next capsule at the usual time. Do not take a double dose to make up for a forgotten dose.




If you stop taking Zavesca


Don't stop Zavesca without talking to your doctor.



If you have any further questions on the use of this medicine, ask your doctor or pharmacist.




Possible Side Effects


Like all medicines, Zavesca can cause side effects, although not everybody gets them.



Very common effects - likely to affect more than 1 in 10 people


The most common side effects are weight loss, tremor, diarrhoea, flatulence (wind), abdominal (stomach) pain.



Common effects - likely to affect less than 1 in 10 people and more than 1 in 100 people


Common side effects of treatment include anorexia (lack of appetite), decreased appetite, headache, dizziness, peripheral neuropathy, paraesthesia (tingling or numbness), abnormal coordination, hypoaesthesia (reduced sensation to touch), dyspepsia (heartburn), nausea (feeling sick), constipation and vomiting, swelling or discomfort in the abdomen (stomach) and thrombocytopenia (reduced levels of blood platelets). The neurological symptoms and thrombocytopenia could be due to the underlying disease.


Other possible side effects are muscular spasms or weakness, fatigue, difficulty sleeping, and less libido.


Most patients get one or more of these side effects, usually at the start of treatment or at intervals during treatment. Most cases are mild and disappear quite quickly. If any of these side effects cause problems, consult your doctor. He or she may reduce the dose of Zavesca or recommend other medicines to help control side effects.



Some patients have had tingling or numbness in the hands and feet. They could be signs of peripheral neuropathy, due to side effects of Zavesca or they could be due to existing conditions. Your doctor will perform some tests before and during treatment with Zavesca to assess this (see section 2).



If you do get any of these effects, please report them to your doctor as soon as possible.



If you do lose some weight when you start treatment with Zavesca don't worry. People usually stop losing weight as treatment goes on.



If you get a slight tremor, usually trembling hands, report it to your doctor as soon as possible. The tremor often disappears without needing to stop the treatment. Sometimes your doctor will need to reduce the dose or stop Zavesca treatment to stop the tremor.



If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.



For storage and other information, please turn over.




How To Store Zavesca


Keep out of the reach and sight of children.


Do not use Zavesca after the expiry date stated on the carton.


Store below 30 °C.



Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.




Further Information



What Zavesca contains



The active substance is miglustat 100 mg.



Other ingredients in the capsule are:


Sodium starch glycollate,


Povidone (K30),


Magnesium stearate.



Other ingredients in the capsule shell are:


Gelatin,


Water,


Titanium dioxide (E171).



Other ingredients in the Printing ink are:


Black iron oxide (E172)


Shellac.




What Zavesca looks like and contents of the pack


Zavesca is a white 100 mg capsule with “OGT 918” printed in black on the cap and “100” printed in black on the body.


Box of 4 blister strips, each blister strip containing 21 capsules providing a total of 84 capsules.




Marketing Authorisation Holder:



Actelion Registration Ltd

BSI Building 13th Floor

389 Chiswick High Road

London

W4 4AL

United Kingdom




Manufacturer responsible for batch release:



Actelion Pharmaceuticals Deutschland GmbH

Basler strasse 63-65

79100 Freiburg

Germany



For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder.




United Kingdom

Actelion Pharmaceuticals UK Ltd

Tel:+44-(0)845 075 0555




This leaflet was last approved in: June 2010


This medicine has been authorised under "Exceptional Circumstances". This means that because of the rarity of this disease it has been impossible to get complete information on this medicine. The European Medicines Agency (EMA) will review any new information on the medicine every year and this leaflet will be updated as necessary.


Detailed information on this medicine is available on the European Medicines Agency (EMA) website: http://www.ema.europa.eu. There are also links to other websites about rare diseases and treatments.